Not like we needed any additional evidence that the Medtronic diabetes franchise is having a very difficult time more came along yesterday when IntriCon, one of their key suppliers reported results. Per the earnings release;
“Revenue in IntriCon’s Medical business in the first quarter of 2020 was $16.4 million, a decrease from $20.8 million in the comparable prior-year period. The year over year decline was driven primarily by the COVID-19 impact on diabetes, one-time revenue recognition adjustment, partially offset by medical coil demand.”
Just as a reminder Medtronic is Intricon’s single largest customer . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.